Cost-effectiveness of allergen immunotherapy.
Journal
Current opinion in allergy and clinical immunology
ISSN: 1473-6322
Titre abrégé: Curr Opin Allergy Clin Immunol
Pays: United States
ID NLM: 100936359
Informations de publication
Date de publication:
18 Sep 2024
18 Sep 2024
Historique:
medline:
4
10
2024
pubmed:
4
10
2024
entrez:
4
10
2024
Statut:
aheadofprint
Résumé
Allergic rhinitis is a relevant and global health problem affecting up to 5-50% of the general population and its prevalence is increasing due to climate change and pollution among other factors and counts among the 10 most frequent reasons for medical consultation, generating an important economic impact. Allergen immunotherapy (AIT) is the only allergy-disease-modifying treatment and there is plenty of evidence of its effectiveness with regards subcutaneous and oral routes of AIT.This narrative review article examines published literature in the last 24 months regarding the pharmacoeconomics of AIT versus standard of care treatment (SOC) for the treatment of allergic rhinitis and asthma. Farraia et al. assessed in 2022 subcutaneous immunotherapy (SCIT, _438/$500.28) and sublingual immunotherapy (SLIT) (_1021/$1116.19) plus symptomatic treatment versus SOC treatment in children with HDM-driven allergic asthma, measuring QALYs, decrease of medication, decrease of exacerbations and symptoms. They used the cost-effective threshold: _18 482.80 ($21 110.14), finding that AIT is cost-effective.Also, SCIT and SLIT plus symptomatic treatment was assessed versus SOC treatment in children with grass pollen allergic rhinitis. The authors concluded that SCIT (_933/$1065.67) and SLIT (_1408/ $1608.22) seem cost-effective, particularly SCIT. Allergen immunotherapy is cost-effective in the management of allergic rhinitis and asthma as compared with SOC alone. As most studies consider only during-treatment costs and no long-term benefits or preventive effects are being assessed, the real cost-effectiveness of allergen immunotherapy could be even higher.
Identifiants
pubmed: 39364915
doi: 10.1097/ACI.0000000000001028
pii: 00130832-990000000-00154
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Références
De La Hoz Caballer B, Rodríguez M, Fraj J, et al. Allergic rhinitis and its impact on work productivity in primary care practice and a comparison with other common diseases: the Cross-sectional study to evAluate work Productivity in allergic Rhinitis compared with other common dIseases (CAPRI) study. Am J Rhinol Allergy 2012; 26:390–394.
Bousquet J, Khaltaev N, Cruz AA, et al. Review article Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 Review Group: Prim Care 2008;63:8–160.
Montoro J, Antolín-Amérigo D, Artés M, et al. Impact of climate change-related environmental factors on the allergens production and the epidemiology and severity of allergic pathologies. J Investig Allergol Clin Immunol 2024; 0 doi: 10.18176/jiaci.0988. [Epub ahead of print].
doi: 10.18176/jiaci.0988.
Lamb CE, Ratner PH, Johnson CE, et al. Economic impact of workplace productivity losses due to allergic rhinitis compared with select medical conditions in the United States from an employer perspective. Curr Med Res Opin 2006; 22:1203–1210.
Hellgren J, Cervin A, Nordling S, et al. Allergic rhinitis and the common cold--high cost to society. Allergy 2010; 65:776–783.
Farraia M, Paciência I, Castro Mendes F, et al. Cost-effectiveness analysis of house dust mite allergen immunotherapy in children with allergic asthma. Allergy 2022; 77:2688–2698.
Farraia M, Paciência I, Castro Mendes F, et al. Cost-effectiveness analysis of grass pollen specific immunotherapy in children with allergic rhinitis compared to the standard of care symptomatic treatment in Portugal. Eur Ann Allergy Clin Immunol 2023; 55:212–228.
Di Bona D, Bilancia M, Albanesi M, et al. Cost-effectiveness of grass pollen allergen immunotherapy in adults. Allergy 2020; 75:2319–2329.
Green W, McMaster J, Babela R, Buchs S. Cost-effectiveness of the SQ HDM SLIT-tablet for the treatment of allergic asthma in three Eastern European Countries. Eur Ann Allergy Clin Immunol 2019; 51:68–74.
Cox LS, Murphey A, Hankin C. The cost-effectiveness of allergen immunotherapy compared with pharmacotherapy for treatment of allergic rhinitis and asthma. Immunol Allergy Clin North Am 2020; 40:69–85.
Meadows A, Kaambwa B, Novielli N, et al. A systematic review and economic evaluation of subcutaneous and sublingual allergen immunotherapy in adults and children with seasonal allergic rhinitis. Health Technol Assess 2013; 17:vi xi–xiv, 1-322.
Roberts G, Pfaar O, Akdis CA, et al. EAACI Guidelines on Allergen Immunotherapy: allergic rhinoconjunctivitis. Allergy 2018; 73:765–798.
Hankin CS, Cox L, Lang D, et al. Allergy immunotherapy among Medicaid-enrolled children with allergic rhinitis: patterns of care, resource use, and costs. J Allergy Clin Immunol 2008; 121:227–232.
Hankin CS, Cox L, Lang D, et al. Allergen immunotherapy and healthcare cost benefits for children with allergic rhinitis: a large-scale, retrospective, matched cohort study. Ann Allergy Asthma Immunol 2010; 104:79–85.
Hankin CS, Cox L, Bronstone A, Wang Z. Allergy immunotherapy: reduced healthcare costs in adults and children with allergic rhinitis. J Allergy Clin Immunol 2013; 131:1084–1091.
Ariano R, Berto P, Tracci D, et al. Pharmacoeconomics of allergen immunotherapy compared with symptomatic drug treatment in patients with allergic rhinitis and asthma. Allergy asthma Proc 2006; 27:159–163.
Creticos PS, Reed CE, Norman PS, et al. Ragweed immunotherapy in adult asthma. N Engl J Med 1996; 334:501–506.
Berto P, Frati F, Incorvaia C, et al. Comparison of costs of sublingual immunotherapy and drug treatment in grass-pollen induced allergy: results from the SIMAP database study. Curr Med Res Opin 2008; 24:261–266.
Schädlich PK, Brecht JG. Economic evaluation of specific immunotherapy versus symptomatic treatment of allergic rhinitis in Germany. Pharmacoeconomics 2000; 17:37–52.
Berto P, Passalacqua G, Crimi N, et al. Economic evaluation of sublingual immunotherapy vs symptomatic treatment in adults with pollen-induced respiratory allergy: the Sublingual Immunotherapy Pollen Allergy Italy (SPAI) study. Ann Allergy Asthma Immunol 2006; 97:615–621.
Bachert C, Vestenbaek U, Christensen J, et al. Cost-effectiveness of grass allergen tablet (GRAZAX) for the prevention of seasonal grass pollen induced rhinoconjunctivitis - a Northern European perspective. Clin Exp Allergy 2007; 37:772–779.
Petersen KD, Gyrd-Hansen D, Dahl R. Health-economic analyses of subcutaneous specific immunotherapy for grass pollen and mite allergy. Allergol Immunopathol (Madr) 2005; 33:296–302.
Nasser S, Vestenbaek U, Beriot-Mathiot A, Poulsen PB. Cost-effectiveness of specific immunotherapy with Grazax in allergic rhinitis co-existing with asthma. Allergy 2008; 63:1624–1629.
Poulsen PB, Pedersen KM, Christensen J, Vestenbaek U. Economic evaluation of a tablet-based vaccination against hay fever in Denmark. Ugeskr Laeger 2008; 170:138–142.
Keiding H, Jørgensen KP. A cost-effectiveness analysis of immunotherapy with SQ allergen extract for patients with seasonal allergic rhinoconjunctivitis in selected European countries. Curr Med Res Opin 2007; 23:1113–1120.
Ronaldson S, Taylor M, Bech PG, et al. Economic evaluation of SQ-standardized grass allergy immunotherapy tablet (Grazax(®)) in children. Clinicoecon Outcomes Res 2014; 6:187–196.
Westerhout KY, Verheggen BG, Schreder CH, Augustin M. Cost effectiveness analysis of immunotherapy in patients with grass pollen allergic rhinoconjunctivitis in Germany. J Med Econ 2012; 15:906–917.
Verheggen BG, Westerhout KY, Schreder CH, Augustin M. Health economic comparison of SLIT allergen and SCIT allergoid immunotherapy in patients with seasonal grass-allergic rhinoconjunctivitis in Germany. Clin Transl Allergy 2015; 5:1.
Reinhold T, Brüggenjürgen B. Cost-effectiveness of grass pollen SCIT compared with SLIT and symptomatic treatment. Allergo J Int 2017; 26:7–15.
Asaria M, Dhami S, van Ree R, et al. Health economic analysis of allergen immunotherapy for the management of allergic rhinitis, asthma, food allergy and venom allergy: a systematic overview. Allergy 2018; 73:269–283.
Shaker MS, Mosnaim G, Oppenheimer J, et al. Health and economic outcomes of home maintenance allergen immunotherapy in select patients with high health literacy during the COVID-19 pandemic: a cost-effectiveness analysis during exceptional times. J Allergy Clin Immunol Pract 2020; 8:2310–2321e4.
Najib M, Westerhout KY, Verheggen B, Schreder CH. Impact of allergen immunotherapy on symptom-free days and healthcare costs in patients with grass pollen-induced allergic rhinitis in Germany. Value Health 2014; 17:A597.